tapentadol IR

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Low Back PainOsteoporosisJoint Disease

237 competitors in Low Back Pain

#DrugCompanyPhaseTrials

1

Arcoxia

Novartis

Phase 3

12

Tofranil

Sanofi

Phase 3

13

Suboxone

IIndivior Inc.

Phase 3

44

Tylenol

KKenvue Brands

Phase 3

35

Tanezumab

Pfizer

Phase 3

46

Anjeso

Boehringer Ingelheim

Phase 3

17

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

18

Xylocaine

MMEDRx USA, Inc.

Phase 3

19

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

—10

Remicade

OOrganon and Co

Phase 3

—Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoporosis1 trial

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

Completed·Johnson & Johnson·Phase 3·NCT00771758·108 enrolled

Oxycodone1 trial

Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.··NCT01545778·646,620 enrolled

Low back pain1 trial

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00594516·117 enrolled

Effectiveness1 trial

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

Completed·Johnson & Johnson·Phase 3·NCT01813890·60 enrolled

Interaction1 trial

Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)

Completed·GGrünenthal GmbH·Phase 1·NCT03979989·32 enrolled

4 more indications

Joint Disease1 trial

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00784277·597 enrolled

Acute Pain1 trial

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy

Completed·Johnson & Johnson·Phase 3·NCT01516008·353 enrolled

Hip Replacement Surgery1 trial

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00364533·367 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery

Completed·Johnson & Johnson·Phase 3·NCT00814580·382 enrolled

Details

Drug Info

Related News